Cardiovascular Disease

Ajmaline (Standard) is the analytical standard of Ajmaline. This product is intended for research and analytical applications. Ajmaline (Cardiorythmine) is a sodium channel blocking, class 1A anti-arrhythmic agent. Ajmaline blocks HERG currents with an IC₅₀ of 1 μM in HEK cells and 42.3 μM in Xenopus oocytes. Ajmaline can be used for the research of the ventricular tachyarrhythmia.

Ifetroban sodium (Standard) is the analytical standard of Ifetroban sodium (HY-105218A). This product is intended for research and analytical applications. Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.

Pimobendan-d₄ (UD-CG115-d₄) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

CE3F4 (Standard) is the analytical standard of CE3F4 (HY-108539). This product is intended for research and analytical applications. CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC₅₀s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.

FR-229934 (Standard) is the analytical standard of FR-229934 (HY-105686). This product is intended for research and analytical applications. FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction.

Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.

Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

TA-02 (Standard) is the analytical standard of TA-02 (HY-100115). This product is intended for research and analytical applications. TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).

TT-301 hydrochloride is a small-molecule immunomodulator capable of penetrating the blood-brain barrier. TT-301 hydrochloride exerts neuroprotective effects by binding to IL-1β, downregulating STAT3 expression, and modulating the JAK-STAT signaling pathway, thereby inhibiting microglial activation and the release of proinflammatory mediators, and alleviating neuroinflammation and brain edema. TT-301 hydrochloride is used in research on traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, muscle wasting and atrophy, and periodontal disease.

NCX899 is a NO-releasing derivative of enalapril, and shows inhibitory activity against angiotensin-converting enzyme (ACE) activity.

Tafluprost (Standard) is the analytical standard of Tafluprost. This product is intended for research and analytical applications. Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma[4].

FK-739 (free base) is an angiotensin II type 1 (AT1) receptor antagonist used in the study of hypertension.

LY 186126 a Indolidan analog, is a phosphodiesterase (PDE) inhibitor. LY 186126 binds to cardiac sarcoplasmic reticulum PDE with high affinity, with a K_d of 5.6 nM.

Sacubitril-d₅ (AHU-377-d₅) hemicalcium is deuterium-labeled Sacubitril hemicalcium (HY-15407A).

1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine (PC(16:0/8:0)) is a phosphatidylcholine glycerophospholipid. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine promotes platelet aggregation and flow-induced platelet-dependent thrombus formation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is a valid biomarker for CAD risk, severity, and subtype differentiation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is suitable for basic research on various types of coronary artery disease.

N-trans-Caffeoyltyramine (Standard) is the analytical standard of N-trans-Caffeoyltyramine (HY-N8241). This product is intended for research and analytical applications. N-TRANS-CaffeoyLtyramine is an effective inflammatory response regulator, which has antioxidant activity and anticoagulation effects.

GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

Guanadrel is an orally active postganglionic adrenergic inhibitor of spiroketal. Guanadre can be used in anti-hypertensive studies.

ONO-6240 is a platelet-activating factor antagonist. ONO-6240 prevents EOS infiltration into airway. ONO-6240 can be used in the study of asthmatic.

Moxonidine-d₃ (BDF5895-d₃) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.